

Source

Monoclonal Anti-Human-IgG-Fc Antibody, Mouse IgG1 is a chimeric monoclonal antibody recombinantly expressed from CHO cells, which combines the variable region of a mouse monoclonal antibody with mouse IgG1 constant domain. The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with IgG Fc.

Isotype

Mouse IgG1 | Kappa

Specificity

This product is a specific antibody specifically reacts with IgG Fc.

Application

ELISA

Purity

>95% as determined by SDS-PAGE.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20 to -70°C for 12 months in lyophilized state from date of receipt;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE




Monoclonal Anti-Human-IgG-Fc Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With <u>Star Ribbon Pre-stained Protein Marker</u>).

Bioactivity-Elisa






Monoclonal Anti-Human-IgG-Fc Antibody, Mouse IgG1 (6F11C8) ELISA
0.2µg of Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) per well



Immobilized Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (MALS verified) (Cat. No. SPD-M402a) at $2\mu g/mL$ (100 $\mu L/well$) can bind Monoclonal Anti-Human-IgG-Fc Antibody, Mouse IgG1 (6F11C8)(Cat. No. IGG-S307) with a linear range of 0.05-3.13 ng/mL (QC tested).

Detection of Monoclonal Anti-Human-IgG-Fc Antibody, Mouse IgG1 (6F11C8) by ELISA Assay



Immobilized Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG2 (AM359b) (MALS verified) (Cat. No. SPD-M400a), Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG3 (AM359b) (MALS verified) (Cat. No. SPD-M401a), Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (MALS verified) (Cat. No. SPD-M402a) and Human ACE2 / ACEH Protein, Fc Tag (MALS verified) (Cat. No. AC2-H5257) can bind Monoclonal Anti-Human-IgG-Fc Antibody, Mouse IgG1 (6F11C8)(Cat. No. IGG-S307). The antibody does not bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA1 (AM130) (MALS verified) (Cat. No. S1N-M164) and Human CD19 (20-291) Protein, His Tag DMF Filed (Cat. No. CD9-H52H2) (Routinely tested).

Background

Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport).

Clinical and Translational Updates

